March 2010
M	T	W	T	F	S	S
« Nov		Apr »
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Pharmacy Drugs

Random Posts

Informa Healthcare Journals To Unite On One Platform - Pharmaceutical Science And Medicine Journals Create Robust Information Service For Customers
First Patient Enrolled In Regeneron And Bayer HealthCare VEGF Trap-Eye Phase 3 Program In Central Retinal Vein Occlusion
RISPERDAL CONSTA (risperidone) Long-Acting Treatment May Improve Health Outcomes And Reduce Hospitalizations In Patients With Schizophrenia
Death Reported with Improper Administration of Flu Drug
Drug Companies Defend Acetaminophen as FDA Considers Restrictions
Medivation Selects ProTrials To Conduct International Phase III Clinical Trials
American Heart Association Late-Breaking Clinical Trial Report: Continuous Flow Heart Pump Improves Survival More Than Pulsatile Type
FDA Expands Flu Vaccine Indication
Washington State Drops Budget Provision That Would Have Cut Medicaid Pharmacy Payments
Medtronic Completes Enrollment In International Post-Market Study Of Resolute Drug-Eluting Stent

Lytix Biopharma AS Announces Regulatory Approval By Norwegian And Swedish Authorities To Commence Phase I Clinical Trial Of OncoporeTM In Cancer

Posted by: admin in Pharmacy Drugs on March 21st, 2010

The Norwegian pharmaceutical company Lytix Biopharma AS announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

According to Lytix Biopharma CEO Gunnar Sælid, “We are delighted to announce the regulatory approval by the Norwegian and Swedish Authorities to test our very interesting experimental drug OncoporeTM (LTX-315) in the clinic. I am extremely pleased with the efforts put in by our Drug Development teams this year, with all projects progressing well according to our plans. For the Company this is an important study, validating the attractiveness of our platform in oncology. We will now have two programs in clinical trials; on the one hand our topical antimicrobial drug, and now our novel treatment for cancer”.

In preclinical models LTX-315 has demonstrated the ability to effect necrotic killing of cancer cells. Simulatenously it also causes the release of danger signals from the stressed and dying cells that trigger a beneficial activation of the immune system.

“The study will start in the beginning of 2010 and will be run at two centers, The Norwegian Radium Hospital - National Hospital in Oslo, as well as the Karolinska University Hospital in Stockholm, Sweden. Initially, the Phase I study will establish a safe and tolerated dose of LTX-315 when given to solid tumours amenable to injection. OncoporeTM (LTX-315) has the potential to becoming a valuable new agent for the treatment of cancer”, says Jon Amund Eriksen, Director of Product Development, Oncology at Lytix Biopharma AS. The clinical trial is supported by grants from The Norwegian Cancer Association (”Kreftforeningen”), The Norwegian Research Council (”Forskningsrådet”) and Innovation Norway (”Innovasjon Norge”).

About OncoporeTM (LTX-315)

LTX-315 is an investigational treatment for cancer based on the biological principle of innate immune effectors, lytic peptides. The drug recognises charges in cell membranes and, in a dose dependent manner, induces immunogenic cell stressing and rapid cell lysis. When injected intra-tumorally LTX-315 causes dramatic and rapid cell lysis and tumour necrosis. The drug has been tested in in vitro and in vivo models, and has undergone formal preclinical safety and toxicology studies. The Phase I/II study is expected to commence in the beginning of 2010.